This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Development of Magnetic Resonance Spectroscopy (MRS) Biomarkers of Tumor Metabolism (MK-0000-145) (MRS Tumor)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01138813
First received: June 4, 2010
Last updated: October 9, 2015
Last verified: October 2015
  Purpose

This study will evaluate the test-retest repeatability of lactate and other metabolites measured by single voxel magnetic resonance spectroscopy (MRS) and multi-voxel magnetic resonance spectroscopic imaging experiments (MRSI) in tumor tissue in patients radiographically diagnosed with glioma.

These measurements will test whether the concentration of lactate in tumor will be higher than the concentration of lactate in normal tissue of the same patient.


Condition
Glioma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Development of Magnetic Resonance Spectroscopy (MRS) Biomarkers of Tumor Metabolism

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • The test-retest repeatability of lactate and other metabolites when measured by multi-voxel MRSI in tumor tissue [ Time Frame: 90 minutes ]
  • The test-retest repeatability of lactate and other metabolites when measured by single voxel MRS [ Time Frame: 90 minutes ]

Secondary Outcome Measures:
  • The geometric mean fold rise (GMFR) in the concentrations of lactate and each of the other metabolites for tumor/normal tissue [ Time Frame: 90 minutes ]
  • The test-retest repeatability of lactate and other metabolites when measured by multi-voxel MRSI in normal tissue [ Time Frame: 90 minutes ]
  • True geometric mean ratio (GMR) of the MRSI/SV MRS concentration values [ Time Frame: 90 minutes ]
  • The mean levels of each of the metabolites will be summarized by tumor grade and type [ Time Frame: 90 minutes ]
  • The correlation between in vivo (measured by MRSI) and in vitro levels of lactate and other metabolites in tumors [ Time Frame: 90 minutes ]
  • The within day and between day standard deviations for each metabolite [ Time Frame: 90 minutes ]

Biospecimen Retention:   Samples With DNA
Tissue

Enrollment: 8
Study Start Date: March 2009
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Male and female patients aged 18-70 years old with newly diagnosed operable glioma of grade II or higher

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Male and female patients aged 18-70 years old with newly diagnosed operable glioma of grade II or higher
Criteria

Inclusion Criteria:

  • Male and female patients aged 18-70 years old with newly diagnosed operable glioma of grade II or higher which is > 3cm in diameter based on radiographic examination
  • Patients about to receive biopsy or resection of newly diagnosed glioma

Exclusion Criteria:

  • Contraindication to magnetic resonance imaging (MRI): e.g. cardiac pacemaker, metallic implants, known contrast allergy, and pregnancy
  • Impaired renal function
  • Current or previous chemotherapy, radiation, or other tumor treatment excluding steroids
  • Tumor location extra-cerebral, temporal, or in close proximity to frontal sinus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01138813

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Publications:
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01138813     History of Changes
Other Study ID Numbers: 0000-145
145
2010_027
Study First Received: June 4, 2010
Last Updated: October 9, 2015

Keywords provided by Merck Sharp & Dohme Corp.:
magnetic resonance spectroscopy (MRS)
lactate editing
metabolite content
glioma

Additional relevant MeSH terms:
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue

ClinicalTrials.gov processed this record on July 26, 2017